Compare · BIIB vs PTHS
BIIB vs PTHS
Side-by-side comparison of Biogen Inc. (BIIB) and Pelthos Therapeutics Inc. (PTHS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and PTHS operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $28.68B, about 300.9x PTHS ($95.3M).
- Over the past year, BIIB is up 50.4% and PTHS is up 103.0% - PTHS leads by 52.5 points.
- BIIB has been more active in the news (11 items in the past 4 weeks vs 6 for PTHS).
- BIIB has more recent analyst coverage (25 ratings vs 6 for PTHS).
- Company
- Biogen Inc.
- Pelthos Therapeutics Inc.
- Price
- $200.13+3.00%
- $27.50+4.60%
- Market cap
- $28.68B
- $95.3M
- 1M return
- +0.36%
- +5.26%
- 1Y return
- +50.41%
- +102.95%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- AMEX
- IPO
- 2024
- News (4w)
- 11
- 6
- Recent ratings
- 25
- 6
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest BIIB
- Biogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Amendment: Biogen Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Biogen upgraded by Needham with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
- EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
- Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
- UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June
- Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
Latest PTHS
- Pelthos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
- CFO, Treas & Secty Francis Knuettel Ii returned 13,947 shares to the company and sold $40,265 worth of shares (1,500 units at $26.84), decreasing direct ownership by 42% to 19,525 units (SEC Form 4)
- SEC Form 144 filed by Pelthos Therapeutics Inc.
- Pelthos Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Leadership Update, Financial Statements and Exhibits
- Director Friedberg Ezra M covered exercise/tax liability with 144 shares, decreasing direct ownership by 0.18% to 81,883 units (SEC Form 4) (withholding obligation)
- Amendment: SEC Form SCHEDULE 13G/A filed by Pelthos Therapeutics Inc.
- Pelthos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Pelthos Therapeutics Inc.
- Pelthos Therapeutics Announces First Quarter 2026 Financial Results